Skip to main content

Table 1 Subjects' Demographic Data at Study Entry

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

 

Study population (n = 74)

Male sex [No. (%)]

61 (82)

Race

 

   African American [No. (%)]

55 (74)

   White [No. (%)]

17 (23)

   Hispanic [No. (%)]

2 (3)

†On LPV/r tablet at entry

 

   No [No. (%)]

49 (66)

   Yes [No. (%)]

25 (34)

On anti-diarrheal drug

 

   No [No. (%)]

67 (92)

   Yes [No. (%)]

6 (8)

On lipid lowering drug

 

   No [No. (%)]

54 (74)

   Yes [No. (%)]

19 (26)

Median age [years (IQR)]

43 (39-47)

Median weight [Kg (IQR)]

80.5 (69.60-88.60)

Median HIV-1 RNA [copies/ml (IQR)]

0.135 (0.05-0.70)

Median CD4 T-cell counts [cell/μl (IQR)]

294 (157-455)

  1. LPV/r, lopinavir/ritonavir; SGC, soft gel capsule; IQR, inter-quartile range.